FDA Approves HYMPAVZI — Pfizer Laboratories Div Pfizer Inc

# FDA Approves Pfizer's HYMPAVZI for Hemophilia A Treatment Pfizer has received FDA approval for HYMPAVZI (marstacimab-hncq), a subcutaneous therapy that expands the company's presence in the rare bleeding disorder market and offers an alternative delivery mechanism to existing hemophilia A treatments. The approval could strengthen Pfizer's competitive position in the specialized hematology market, though adoption will depend on clinical differentiation and reimbursement dynamics relative to established therapies.